All In Biotech

Free tool

FAERS Monitor: Natazia

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022252 or its brand name (Natazia, Dienogest, Estradiol Valerate). Reports on generic versions are filed under their own applications.

Reports

322

Serious

63

20% of reports

Hospitalization

19

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • metrorrhagia35
  • drug dose omission34
  • headache18
  • vaginal haemorrhage15
  • off label use14
  • menstruation delayed12
  • pregnancy on oral contraceptive12
  • nausea11
  • product use issue11
  • amenorrhoea10
  • product use in unapproved indication10
  • inappropriate schedule of drug administration9
  • vomiting9
  • abnormal withdrawal bleeding8
  • menorrhagia8

Reports by year received

View as table
YearReports
201012
201142
201243
201340
201426
201532
201622
201710
201816
201918
202013
20218
202210
20236
20245
20257
202612

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,837 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
abnormal withdrawal bleedingSignal8573.5288.43,983
pregnancy on oral contraceptiveSignal12300.4172.23,273
metrorrhagiaSignal35134.398.24,494
menstruation delayedSignal1272.441.5775
amenorrhoeaSignal1037.320.2318
menorrhagiaSignal826.613.4173
vaginal haemorrhageSignal1522.613.8289
drug dose omissionSignal3413.49.8382
inappropriate schedule of drug administrationSignal98.34.351
product use issueSignal113.82.120
product use in unapproved indicationSignal102.61.49
headache181.91.27
vomiting91.30.70
off label use141.00.60
nausea110.90.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.